1N-acetylation phenotype has been examined in 30 patients with bladder cancer and in 27 controls of similar age.
2 59% of controls and 70% of bladder cancer patients were phenotypically 'slow' acetylators. This difference was not significant (P>0.30).
3 Within phenotypes, isoniazed half life was similar in controls and bladder cancer patients.
4 N-acetylation phenotype is unlikely to be a major determinant in the pathogenesis of bladder cancer in the population studied.
Get full access to this article
View all access options for this article.
References
1.
Clayson, D.B. (1975). Epidemiology of bladder cancer, in The Biology and Clinical Management of Bladder Cancer. (Cooper, E. H. and Williams, R. E. eds) 65-86. Oxford, Blackwell Scientific.
2.
Drayer, D.E. & Reidenberg, M.M. (1977). Clinical consequences of polymorphic acetylation of basic drugs. Clin. Pharmacol. Ther. , 22, 251-257.
3.
Evans, D.A.P., Manley, K.A. & McKusick, V.A. (1960). Genetic control of isoniazid metabolism in man. Br. Med. J., 2, 485-491.
4.
Evans, D.A.P. & White, T.A. (1964). Human acetylation polymorphism. J. Lab. Clin. Med., 63, 394-403.
5.
Farah, F., Taylor, W., Rawlins, M.D. & James, O.F.W. (1977). Hepatic drug acetylation and oxidation: effects of aging in man. Br. Med. J., 2, 155-156.
6.
Lower, G.M., Nillsson, T., Nelson, C.E., Wolf, H., Gamsky, T.E. & Bryan, G.T. (1979). N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environmental Health Perspectives, 29, 71-79.
7.
Maher, J.T., Whitneh, J.M., Chambers, J.S. & Stanonis, D.J. (1957). The quantitative determination of isoniazid and paraaminosalycilic acid in body fluids. Am. Rev. Tuberc. Pulm. Dis., 76, 852-861.
